ScholarLens Back to search
2008•Unpublished venueRequires access

Effects of rivaroxaban and fondaparinux on clotting assays

M Samama, Léna Le Flem, Céline Guinet, Elisabeth Perzborn, Jean-Luc Martinoli, François Depasse

Open publisher page 1 citations

Abstract

Rivaroxaban is an oral, direct Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of venous thromboembolism1 Unlike the indirect, subcutaneously administered FXa inhibitor fondaparinux, the mechanism of action of rivaroxaban is antithrombin independent1 There is no need for routine monitoring of coagulation parameters with rivaroxaban – Rivaroxaban has predictable pharmacokinetics and pharmacodynamics2,3 – Rivaroxaban has a low propensity for drug–drug interactions3–6 – Dietary restrictions are not necessary in patients receiving rivaroxaban7 An optimum clotting assay might be valuable if a physician wants to measure the pharmacodynamic effects of rivaroxaban

About this research paper

What this paper is about

Rivaroxaban is an oral, direct Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of venous thromboembolism1 Unlike the indirect, subcutaneously administered FXa inhibitor fondaparinux, the mechanism of action of rivaroxaban is antithrombin independent1 There is no need for routine monitoring of coagulation parameters with rivaroxaban – Rivaroxaban has predictable pharmacokinetics and pharmacodynamics2,3 – Rivaroxaban has a low propensity for drug–drug interactions3–6 – Dietary restrictions are not necessary in patients receiving rivaroxaban7 An optimum clotting assay might be valuable if a physician wants to measure the pharmacodynamic effects of rivaroxaban

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Rivaroxaban is an oral, direct Factor Xa (FXa) inhibitor in advanced clinical development for the prevention and treatment of venous thromboembolism1 Unlike the indirect, subcutaneously administered FXa inhibitor fondaparinux, the mechanism of action of rivaroxaban is antithrombin independent1 There is no need for routine monitoring of coagulation parameters with rivaroxaban – Rivaroxaban has predictable pharmacokinetics and pharmacodynamics2,3 – Rivaroxaban has a low propensity for drug–drug interactions3–6 – Dietary restrictions are not necessary in patients receiving rivaroxaban7 An optimum clotting assay might be valuable if a physician wants to measure the pharmacodynamic effects of rivaroxaban

Key concepts: Rivaroxaban, Fondaparinux, Medicine, Pharmacodynamics, Pharmacology, Antithrombin, Drug, Pharmacokinetics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Effects of rivaroxaban and fondaparinux on clotting assays — Research Paper | ScholarLens